Sinusitis Clinical Trial
— MERLOTOfficial title:
Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis (MERLOT)
NCT number | NCT01685229 |
Other study ID # | CPR005028 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 1, 2012 |
Est. completion date | August 1, 2015 |
Verified date | February 2019 |
Source | Acclarent |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This post-market study aims to compare health outcomes for Chronic Rhinosinusitis (CRS) patients treated with balloon sinus dilation (BSD) versus continued medical management.
Status | Completed |
Enrollment | 198 |
Est. completion date | August 1, 2015 |
Est. primary completion date | April 1, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: - Males and females aged 19 or greater - Diagnosis of Chronic Rhinosinusitis (CRS) - Failure of appropriate medical management - Radiographic evidence of inflammation of the paranasal sinuses - Surgical candidate - Willing and able to read and sign the Informed Consent Form and remain compliant with the protocol and study procedures - Able to read and understand English Exclusion Criteria: - Not suitable for balloon dilation for all peripheral sinuses that require treatment - Clinically significant illness that may interfere with the evaluation of the study - Patients involved in other clinical studies 30 days prior to study - Pregnant or lactating females - Patients unable to adhere to follow-up schedule or protocol requirements |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Acclarent |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of Change in Chronic Sinusitis Survey (CSS) Score at 24 Weeks Compared to Baseline | The Chronic Sinusitis Survey (CSS) is a 6 question, duration-based survey ("during the past 8 weeks") to evaluate surgical outcomes for CRS patients. The CSS asks three questions each about symptoms and medication usage, yielding a symptom subscore, a medication subscore, and a total score. The duration of symptoms is scored 0 ("7-8 Weeks") to 4 ("0 Weeks") and a total score is normalized from 0 (worst) to 100 (best). The Primary Endpoint is the comparison of change in total CSS score over 24 weeks for subjects electing BSD versus medical management. Change is assessed by using the Mean Change for the CSS total score at 24 weeks compared to baseline. (24-week CSS total score minus Baseline CSS total score). Higher score indicates greater improvement. |
24 weeks post treatment | |
Secondary | Comparison of Change Measured by CSS Medication and Sinusitis Symptom Subscores and Total Score From Baseline | The Chronic Sinusitis Survey (CSS) is a 6 question, duration-based survey ("during the past 8 weeks") used to evaluate surgical outcomes for CRS patients. The CSS asks 3 questions each about symptoms and medication usage, yielding a symptom subscore, a medication subscore, and a total score. The symptom-based section contains pain or pressure, nasal congestion or difficulty to breathe through the nose, and rhinorrhea or postnasal drip. The medication-based section contains: antibiotics, prescription nasal sprays, and sinus medications in pill form. The duration of symptoms is scored 0 ("7-8 Weeks") to 4 ("0 Weeks"), and a total score is normalized from 0 (worst) to 100 (best). The Secondary Endpoint is the comparison of change as measured by average CSS medication and sinusitis symptom sub-scores at 12, 24, and 52 weeks , and average total CSS score at 12 and 52 weeks for subjects electing BSD versus medical management. Higher score indicates greater improvement. | 12, 24, and 52 weeks post treatment | |
Secondary | Change in RSDI | The Rhinosinusitis Disability Index (RSDI) is a 30-question survey which includes 3 individual subscales to measure physical, functional, and emotional scores as well as a total score. There is no specified recall period. Scale values are scored 0 ("Never") to 4 ("Always") and total score ranges from 0 (best) to 120 (worst). Subscores are summed to calculate a total score. Higher score indicates increased impact of sinus disease. The Secondary Endpoint is comparison of change in patient-reported QOL as measured by RSDI total, physical, functional, and emotional sub-scores at 12, 24, and 52 weeks compared to baseline for subjects electing BSD versus medical management. Lower score indicates greater improvement (decreased impact of sinus disease). |
12, 24 and 52 weeks post treatment | |
Secondary | Change in SNOT-20 | The Sino-Nasal Outcome Test (SNOT-20) is a validated questionnaire consisting of 20 symptom-directed questions and quality of life and health utility assessments. Scale values range from 0 (No Problem) to 5 (Problem as bad as it can be). Lower score indicates greater improvement. |
12 weeks, 24 weeks, 52 weeks post treatment | |
Secondary | Change in Disease-specific Medication Usage | 12, 24 and 52 weeks post treatment | ||
Secondary | Missed Days Work/School | 12, 24 and 52 weeks post treatment | ||
Secondary | Number of Sinus-related Medical Care Visits | 12 weeks, 24 weeks, 52 weeks post treatment | ||
Secondary | Number of Sinus Infections | 24 and 52 weeks | ||
Secondary | Number of Subjects Requiring Revision for Subjects Electing BSD | A revision is defined as an endoscopic sinus surgery procedure on sinuses successfully dilated during index (BSD) procedure due to documented worsening of condition related to those sinuses after the index (BSD) procedure. | 52 weeks | |
Secondary | Number of Medical Management Subjects Electing to Cross-over to Balloon Sinus Dilation Procedure | 52 weeks | ||
Secondary | Post-operative Return to Normal Activity (RTNA) | 2 weeks post treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03584178 -
The Long-Term Safety of Budesonide for Patients With Chronic Rhinosinusitis
|
N/A | |
Completed |
NCT06016335 -
MRI-based Synthetic CT Images of the Head and Neck
|
N/A | |
Active, not recruiting |
NCT02278484 -
Sinus Balloon Dilation in Pediatric Patients
|
N/A | |
Withdrawn |
NCT02071667 -
Association of Periostin Levels and Chronic Sinusitis
|
N/A | |
Completed |
NCT01420471 -
Medicated Punctured-Glove-Finger Spacer Study
|
Phase 4 | |
Completed |
NCT01118312 -
Study of Asthma and Nasal Steroids
|
Phase 4 | |
Completed |
NCT00645762 -
Balloon REmodeling Antrostomy THErapy Study
|
Phase 2 | |
Active, not recruiting |
NCT03943121 -
The Effects of Steroid-eluting Stent Implant for the Treatment of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
|
N/A | |
Withdrawn |
NCT02900794 -
Gold Laser Vs. Micro-Debriders for Functional Endoscopic Sinus Surgery
|
N/A | |
Terminated |
NCT02630472 -
Topical Irrigation Therapy for CRS
|
Phase 1/Phase 2 | |
Completed |
NCT01442740 -
15-Degree Tilt, Head Up, Feet Down Body Position for Sinus Surgery Patients
|
N/A | |
Completed |
NCT01001039 -
Validation of the Facial and Cephalic Pain Inventory
|
N/A | |
Completed |
NCT01033799 -
Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers
|
N/A | |
Completed |
NCT00242437 -
Hemostatic Matrix in Endoscopic Sinus Surgery
|
Phase 4 | |
Completed |
NCT00335309 -
Maxillary Sinus Irrigation in the Management of Chronic Rhinosinusitis
|
N/A | |
Completed |
NCT00236522 -
A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults.
|
Phase 3 | |
Completed |
NCT01717274 -
Hot Saline Irrigation Study
|
N/A | |
Completed |
NCT01166945 -
Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children
|
N/A | |
Completed |
NCT00747747 -
Sinuclean's Treatment Of Sinusitis' Symptoms
|
Phase 4 | |
Not yet recruiting |
NCT00545961 -
Middle Meatal Bacteriology During Acute Respiratory Infection in Children
|
Phase 4 |